Carbonated drinks, alcohol, spicy foods, fried foods and rich desserts can trigger nausea
While common side effects like nausea and digestive discomfort are well-documented, the emergence of 'Ozempic breath' highlights a less anticipated consequence
GLP-1 Manufacturers Argue Gastroparesis Lawsuits Should Require Contemporaneous Diagnostic Testing Plaintiffs experts have maintained that there are multiple reliable ways to diagnose gastroparesis, which should not require specific testing results that doctors often do not order when the injury first surfaces
Personalization is key to improving long-term adherence and outcomes.
Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027 ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al